CHA Biotech plans to allocate 10,000 square meters within its CGB facility to the K-Bio-CIC Open Innovation Center, with full-scale operations expected to begin in the second half of 2026, according to KBR. CHA Biotech's plan to allocate 10,000 square meters within its CGB facility to the K-Bio-CIC Open Innovation Center, with full-scale operations expected to begin in the second half of 2026, according to KBR, is a direct strategy to integrate international expertise and accelerate advanced biotech R&D.
South Korea has historically nurtured a strong domestic startup ecosystem. However, its next phase of growth is increasingly reliant on actively integrating global partners and capital. This shift is crucial for startups seeking broader market access and advanced R&D opportunities.
South Korea is poised to become a more significant global hub for collaborative innovation, attracting international players and propelling its startups onto the world stage. This strategy involves targeted government funding and corporate initiatives designed to embed its startups directly into international R&D and market ecosystems, expanding South Korea's startup open innovation support by 2026.
A New Hub for Biotech Innovation
CHA Biotech and Thermo Fisher are partnering to build and operate the K-Bio CIC research hub, according to Seoul Economic Daily. Located within CHA Biotech's CGB facility—a 10-story aboveground and 4-story underground building spanning 66,115 square meters, according to KBR—this dedicated space confirms the scale of South Korea's biotech ambition.
The K-Bio CIC research hub will provide tenant firms with tech validation and clinical trial support, according to Seoul Economic Daily. This comprehensive support structure, combined with the substantial physical infrastructure, creates a robust ecosystem designed for biotech startups to scale and innovate. By co-investing in massive, sector-specific hubs like the 10,000 square meter K-Bio-CIC with global partners like Thermo Fisher, South Korea is not just inviting foreign collaboration but actively building the physical infrastructure to embed its strategic industries into the global R&D landscape by 2026.
